Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Theravance BiopharmaTBPH | Open-market sale10b5-1 plan | 06/15 | 06/17 | 13,314 sh3 trades | $16.39avg. | $218,183.18 | −5.4% | |
Theravance BiopharmaTBPH | Open-market sale10b5-1 plan | 03/16 | 03/18 | 31,067 sh3 trades | $13.96avg. | $433,695.36 | −11.8% | |
Theravance BiopharmaTBPH | Open-market sale10b5-1 plan | 25/12/03 | 25/12/05 | 31,067 sh3 trades | $18.75avg. | $582,506.25 | −10.1% | |
Theravance BiopharmaTBPH | Open-market sale10b5-1 plan | 25/11/26 | 25/12/01 | 29,501 sh2 trades | $20.00avg. | $590,020 | −39.8% | |
Theravance BiopharmaTBPH | Open-market saleAmendment | 25/11/11 | 25/11/14 | 45,000 sh3 trades | $17.98avg. | $809,250 | −42.8% | |
Theravance BiopharmaTBPH | Open-market sale | 25/11/11 | 25/11/13 | 59,000 sh3 trades | $18.11avg. | $1,068,250 | −56.1% | |
Theravance BiopharmaTBPH | Open-market sale10b5-1 plan | 25/07/14 | 25/07/16 | 10,000 sh3 trades | $11.39avg. | $113,900 | −3.0% | |
Rhonda FarnumSVP, Comm & Medical Affairs | Theravance BiopharmaTBPH | Open-market sale10b5-1 plan | 25/06/02 | 25/06/04 | 24,000 sh | $11.00 | $264,000 | −6.6% |
Rhonda FarnumSVP, Comm & Medical Affairs | Theravance BiopharmaTBPH | Open-market sale10b5-1 plan | 25/04/21 | 25/04/23 | 4,000 sh | $9.00 | $36,000 | −1.1% |
Rhonda FarnumSVP, Comm & Medical Affairs | Theravance BiopharmaTBPH | Open-market sale10b5-1 plan | 25/01/21 | 25/01/23 | 4,000 sh | $9.00 | $36,000 | −1.3% |
Rhonda FarnumSVP, Comm & Medical Affairs | Theravance BiopharmaTBPH | Open-market sale | 24/11/11 | 24/11/13 | 4,000 sh | $9.00 | $36,000 | −1.2% |
Eli Samaha10% Owner | Theravance BiopharmaTBPH | Open-market buy | 24/08/07 | 24/08/09 | 999,800 sh | $7.80 | $7,798,440 | +11.7% |
Rhonda FarnumSVP, Comm & Medical Affairs | Theravance BiopharmaTBPH | Open-market sale10b5-1 plan | 24/07/10 | 24/07/12 | 4,000 sh | $9.00 | $36,000 | −1.2% |
Theravance BiopharmaTBPH | Open-market buy | 24/05/01 | 24/05/03 | 1,499,124 sh2 trades | $8.75avg. | $13,117,335 | +21.4% | |
Rhonda FarnumSVP, Comm & Medical Affairs | Theravance BiopharmaTBPH | Open-market sale10b5-1 plan | 24/02/22 | 24/02/22 | 1,254 sh | $8.71 | $10,922.34 | −0.4% |
Rhonda FarnumSVP, Comm & Medical Affairs | Theravance BiopharmaTBPH | Open-market sale10b5-1 plan | 23/11/21 | 23/11/22 | 1,378 sh | $10.29 | $14,179.62 | −0.4% |
Richard A. GrahamSVP, Research & Development | Theravance BiopharmaTBPH | Open-market sale10b5-1 plan | 23/11/14 | 23/11/16 | 2,482 sh | $10.22 | $25,366.04 | −0.7% |
Richard A. GrahamSVP, Research & Development | Theravance BiopharmaTBPH | Open-market sale10b5-1 plan | 23/10/16 | 23/10/18 | 2,482 sh | $9.03 | $22,412.46 | −0.7% |
Richard A. GrahamSVP, Research & Development | Theravance BiopharmaTBPH | Open-market sale10b5-1 plan | 23/09/14 | 23/09/18 | 2,482 sh | $9.89 | $24,546.98 | −0.7% |
Rhonda FarnumSVP, Comm & Medical Affairs | Theravance BiopharmaTBPH | Open-market sale10b5-1 plan | 23/08/22 | 23/08/24 | 1,807 sh | $9.47 | $17,112.29 | −0.5% |